Waldenstrom Macroglobulinemia clinical trials at UCSF

2 in progress, 1 open to eligible people

Waldenstrom macroglobulinemia is a slow-growing blood cancer that affects B cells and raises protein in blood. UCSF is testing a new oral drug that works on B cells to kill cancer cells. The early-phase study looks at safety and anti-cancer activity for adults with returning or resistant disease.

Showing trials for

  • NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

    open to eligible people ages 18 years and up

    This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

    San Francisco, California and other locations

  • Oral LOXO-338 in Patients With Advanced Blood Cancers

    Sorry, in progress, not accepting new patients

    The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

    San Francisco, California and other locations

Our lead scientists for Waldenstrom Macroglobulinemia research studies include .

Last updated: